A Dog THC Distribution Study Showed Why Total Radioactivity Should Not Be Reported as Unchanged THC

A 1976 dog experiment found that only part of brain radioactivity after labeled THC represented unchanged THC. Its tissue and subcellular findings therefore cannot be summarized as though every radioactive signal measured active parent drug.

The analytical components were separated

The study compared tolerant and non-tolerant dogs after an intravenous labeled-THC challenge. The abstract identified 46% of brain radioactivity as THC and separately discussed metabolite contributions. Total label and a chemically identified parent-drug fraction answer different questions.

Not every regional difference was significant

Brain-area radioactivity was generally lower in tolerant animals, but only selected regional comparisons reached significance. A broad directional pattern should not be described as a statistically demonstrated decrease in every region. Plasma radioactivity also did not differ significantly between groups.

A subcellular finding suggested rather than proved a mechanism

A lower synaptic-vesicle signal prompted a possible mechanistic interpretation. The authors did not find that the other fraction comparisons explained tolerance. A fraction-associated signal does not independently demonstrate receptor action, subjective effect or functional adaptation.

Interpreting the evidence

For a distribution claim, identify whether the measurement is parent THC, a metabolite or total radioactivity. This animal study does not validate a human brain-to-blood conversion, and its short post-dose sampling cannot establish a complete time course of impairment.

Related reading: interpreting cannabis tolerance claims.

Research reference

Martin BR; Dewey WL; Harris LS; Beckner JS (1976). 3H-delta9-tetrahydrocannabinol tissue and subcellular distribution in the central nervous system and tissue distribution in peripheral organs of tolerant and nontolerant dogs. The Journal of pharmacology and experimental therapeutics. PubMed research record.

This analysis draws on the supplied abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Pilot Mouse Study Found Declining THC and CBNA Antinociception With Repeated Administration

A 2021 pilot study reported strong initial antinociceptive responses to THC and cannabinolic acid, followed by decreasing responses over subsequent days. The evidence concerns adult male mice and experimental mechanical and thermal tests. The study evaluated two nociceptive domains Mechanical and thermal responses were assessed after systemic intraperitoneal administration. Those…

Spread the love

Read Article: A Pilot Mouse Study Found Declining THC and CBNA Antinociception With Repeated Administration

Short-Term THC–Morphine Treatment Produced Different Receptor-Protein Patterns in Mouse Midbrain and Spinal Cord

A 2001 mouse study found different opioid- and cannabinoid-receptor protein patterns across midbrain and spinal cord after short-term THC–morphine treatment. A statement about total receptor change would obscure those tissue-specific comparisons. The comparison included separate treatment groups Investigators assessed THC, morphine and their combination using Western blot measurements. Opioid-receptor protein…

Spread the love

Read Article: Short-Term THC–Morphine Treatment Produced Different Receptor-Protein Patterns in Mouse Midbrain and Spinal Cord

A THC Kinase Study Distinguished Reversing Tolerance From Reducing the Initial Drug Effect

A 2003 study found that selected kinase inhibitors reversed THC antinociceptive tolerance while others did not. One higher-dose intervention reduced THC's acute antinociceptive effect, illustrating a different outcome from reversing tolerance. The panel included useful negatives The study tested interventions directed at several kinases. Some did not affect tolerance under…

Spread the love

Read Article: A THC Kinase Study Distinguished Reversing Tolerance From Reducing the Initial Drug Effect

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us